1. Home
  2. EWTX vs ALEX Comparison

EWTX vs ALEX Comparison

Compare EWTX & ALEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EWTX
  • ALEX
  • Stock Information
  • Founded
  • EWTX 2017
  • ALEX 1870
  • Country
  • EWTX United States
  • ALEX United States
  • Employees
  • EWTX N/A
  • ALEX N/A
  • Industry
  • EWTX Biotechnology: Pharmaceutical Preparations
  • ALEX Real Estate Investment Trusts
  • Sector
  • EWTX Health Care
  • ALEX Real Estate
  • Exchange
  • EWTX Nasdaq
  • ALEX Nasdaq
  • Market Cap
  • EWTX 1.2B
  • ALEX 1.3B
  • IPO Year
  • EWTX 2021
  • ALEX N/A
  • Fundamental
  • Price
  • EWTX $14.58
  • ALEX $17.51
  • Analyst Decision
  • EWTX Buy
  • ALEX Buy
  • Analyst Count
  • EWTX 8
  • ALEX 3
  • Target Price
  • EWTX $40.13
  • ALEX $23.00
  • AVG Volume (30 Days)
  • EWTX 1.2M
  • ALEX 464.5K
  • Earning Date
  • EWTX 05-08-2025
  • ALEX 04-24-2025
  • Dividend Yield
  • EWTX N/A
  • ALEX 5.14%
  • EPS Growth
  • EWTX N/A
  • ALEX 38.72
  • EPS
  • EWTX N/A
  • ALEX 0.85
  • Revenue
  • EWTX N/A
  • ALEX $236,060,000.00
  • Revenue This Year
  • EWTX N/A
  • ALEX N/A
  • Revenue Next Year
  • EWTX N/A
  • ALEX $2.81
  • P/E Ratio
  • EWTX N/A
  • ALEX $20.66
  • Revenue Growth
  • EWTX N/A
  • ALEX 6.41
  • 52 Week Low
  • EWTX $10.60
  • ALEX $15.70
  • 52 Week High
  • EWTX $38.12
  • ALEX $20.30
  • Technical
  • Relative Strength Index (RSI)
  • EWTX 41.67
  • ALEX 60.05
  • Support Level
  • EWTX $13.82
  • ALEX $17.17
  • Resistance Level
  • EWTX $17.30
  • ALEX $17.60
  • Average True Range (ATR)
  • EWTX 1.02
  • ALEX 0.37
  • MACD
  • EWTX 0.32
  • ALEX 0.10
  • Stochastic Oscillator
  • EWTX 30.43
  • ALEX 93.99

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

About ALEX Alexander & Baldwin Inc. REIT Holding Company

Alexander & Baldwin Inc is a Hawaii commercial real estate company. The group owns, operates, and manages million square feet of retail, industrial, and office space in Hawaii. It is a real estate investment trust (REIT) and the owner of grocery and drug-anchored retail centers in the state. It functions through two segments namely Commercial Real Estate and Land Operations. The Commercial Real Estate segment owns and manages retail, industrial spaces, and also urban ground leases in Hawaii, thereby accounting for a majority of the company's revenue. The Land Operations segment actively manages the company's land and real estate-related assets and makes optimum utilization of these assets. Geographically, the activities are carried out across the United States.

Share on Social Networks: